kyun09
- Sep 24
- 1 min read

Awarded 2022 NIH/NCI R01 Grant

Humbled and thrilled to receive our NIH/NCI R01 grant!

It is a 5-year $3.07M grant for a prospective clinical trial with our E-Slice assay to predict Triple Negative Breast Cancer patient treatment responses to standard of care.

Huge thanks to collaborators Dr. Kyuson Yun, Houston Methodist/Weill-Cornell Med, and Dr. Naoto Ueno at MD Anderson Cancer Center. #E-Slice #NIH #NCI # R01 #TNBC #MDACC #HMRI #Breastcancer #Immunotherapy #Cancertreatment #Precisiononcology

Recent Posts

See All

Top 10 Most Promising Company, Once Again

At the 11th annual Texas Life Science Forum, held on November 8, 2022, EMPIRI Inc. was once again recognized as one of the Rice Alliance Most Promising Life Science Companies for our E-Slice technolog

Gulf Coast Consortia Single Cell Omics 2022 Presentation

EMPIRI scientist Thomas Gallup presents his poster "Single Cell RNA-sequencing Analysis from Clinical Trials Needle Biopsy Cores" at the GCC Single Cell Omics on October 26, 2022. GCC, an inter-insti

Texas Life Science Forum "Most Promising Company" Award

EMPIRI INC.

Awarded 2022 NIH/NCI R01 Grant

Recent Posts